Back

TerraFlow, A New High Parameter Data Analysis Tool, Reveals Systemic T-cell Exhaustion and Dysfunctional Cytokine Production in Classical Hodgkin Lymphoma

Diefenbach, C.; Freeman, D.; Lam, L.; Le, T.; Alexandre, J.; Raphael, B.; Grossbard, M.; Kaminetzky, D.; Ruan, J.; Chattopadhyay, P. K.

2021-09-12 allergy and immunology
10.1101/2021.09.10.21263388
Show abstract

The incredible variety of proteins associated with immune responses presents a major challenge in immune monitoring. When combinations of these proteins are measured, cell types that influence disease can be precisely identified. Here, we introduce TerraFlow, a novel data analysis tool that performs an exhaustive search of disease-associated cell populations from high-parameter flow cytometry experiments. Using a newly generated dataset, from 24-color immune checkpoint-focused and 18-color immune function-focused experiments, we apply TerraFlow to classical Hodgkin lymphoma (cHL), where systemic T-cell immunity has not been investigated in detail. We reveal novel immune perturbations in newly diagnosed cHL, as well as persistent immune perturbations after treatment. Newly diagnosed patients have elevated levels of activated (CD278+), exhausted (e.g., CD366+ and CD152+ phenotypes), and IL17-expressing cells, along with diminished levels of naive and central memory (CD127+) T-cells and fewer IFN{gamma}+ and TNF+ T-cells. Exhaustion signatures are reduced with treatment, but compared to healthy individuals, treated patients still exhibit more activated (CD278+ phenotypes), exhausted (CD366+), and IL17-expressing cells. Notably, TerraFlow identifies more phenotypic differences between patient groups than FlowSOM and CellCNN, often with better predictive power. Finally, we introduce a new non-gating approach for data analysis that obviates the need for time-consuming and subjective setting of fluorescence thresholds. Our results benchmark TerraFlow against common methods, provide mechanistic support for past reports of immune deficiency in cHL, and provide a roadmap for future immunotherapy and biomarker studies.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Nature Communications
based on 483 papers
Top 3%
15.6%
2
eLife
based on 262 papers
Top 2%
7.7%
3
Immunity
based on 11 papers
Top 0.1%
5.9%
4
Journal of Experimental Medicine
based on 10 papers
Top 0.2%
4.8%
5
Cell Genomics
based on 34 papers
Top 0.3%
4.6%
6
Cell Reports Medicine
based on 49 papers
Top 0.7%
4.6%
7
Nature Medicine
based on 88 papers
Top 3%
2.8%
8
PLOS Computational Biology
based on 141 papers
Top 4%
2.8%
9
Nature Immunology
based on 14 papers
Top 0.4%
2.8%
50% of probability mass above
10
Allergy
based on 13 papers
Top 0.8%
2.5%
11
Communications Biology
based on 36 papers
Top 0.7%
2.5%
12
The Journal of Immunology
based on 19 papers
Top 0.7%
2.5%
13
Science Advances
based on 52 papers
Top 1.0%
2.3%
14
Science Translational Medicine
based on 40 papers
Top 2%
2.3%
15
Bioinformatics
based on 24 papers
Top 0.6%
2.3%
16
Scientific Reports
based on 701 papers
Top 64%
2.3%
17
Cell
based on 28 papers
Top 1%
1.6%
18
Proceedings of the National Academy of Sciences
based on 100 papers
Top 7%
1.6%
19
Science Immunology
based on 15 papers
Top 0.7%
1.6%
20
Nature Genetics
based on 72 papers
Top 7%
1.3%
21
PLOS ONE
based on 1737 papers
Top 91%
1.3%
22
Journal of Clinical Investigation
based on 50 papers
Top 2%
1.3%
23
The American Journal of Human Genetics
based on 77 papers
Top 6%
1.3%
24
Frontiers in Immunology
based on 140 papers
Top 5%
1.3%
25
Brain
based on 69 papers
Top 6%
1.2%
26
Cell Reports
based on 25 papers
Top 1%
1.2%
27
iScience
based on 74 papers
Top 7%
0.8%
28
Clinical Immunology
based on 12 papers
Top 1%
0.8%
29
npj Vaccines
based on 18 papers
Top 0.7%
0.8%
30
Nature
based on 58 papers
Top 9%
0.8%